Further, we showed an increase in periconceptional use of second-line noninsulin ADMs, particularly GLP-1 receptor agonists in the US, highlighting that there has been a shift in how T2D in reproductive-aged women is treated. Here, GLP1R is linked to type 2 diabetes mellitus.